Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

12345678910
Date   Source Headline
28th Jan 20257:00 amRNSEnhertu approved in US for breast cancer post ET
20th Jan 20257:00 amRNSDato-DXd approved in US for HR+ breast cancer
17th Jan 20257:00 amRNSCalquence combination approved in US for 1L MCL
2nd Jan 20253:00 pmRNSTotal Voting Rights
24th Dec 20247:00 amRNSDato-DXd NSQ NSCLC application withdrawn in EU
23rd Dec 20247:00 amRNSTagrisso approved in EU based on LAURA trial
16th Dec 20247:00 amRNSDirectorate Change
5th Dec 20247:00 amRNSImfinzi approved in US for limited-stage SCLC
4th Dec 20241:45 pmRNSAstraZeneca appoints Iskra Reic EVP International
2nd Dec 20243:05 pmRNSBlock listing Interim Review
2nd Dec 20243:00 pmRNSTotal Voting Rights
25th Nov 20247:00 amRNSTruqap improved rPFS in advanced prostate cancer
20th Nov 20244:00 pmRNSDirector/PDMR Shareholding
18th Nov 20247:00 amRNSTagrisso recommended for EU approval - LAURA
15th Nov 20242:00 pmRNSDirector/PDMR Shareholding
15th Nov 202410:00 amRNSDirector/PDMR Shareholding
13th Nov 20244:00 pmRNSDirector/PDMR Shareholding
12th Nov 20247:10 amRNSAstraZeneca invests $3.5 billion in US
12th Nov 20247:05 amRNSKOMET Phase III trial met primary endpoint
12th Nov 20247:00 amRNS9M and Q3 2024 Results
12th Nov 20247:00 amRNSDato-DXd new BLA submitted, NSQ BLA withdrawn
8th Nov 20247:00 amRNSTezspire nasal polyps trial met primary endpoints
5th Nov 20244:49 pmRNSAZN share price movement
1st Nov 20243:00 pmRNSTotal Voting Rights
30th Oct 20241:00 pmRNSAZN China President under investigation
21st Oct 20247:00 amRNSWainzua recommended for approval in the EU
7th Oct 20249:30 amRNSAstraZeneca licenses lipid lowering Lp(a) asset
1st Oct 20243:00 pmRNSTotal Voting Rights
26th Sep 20247:00 amRNSTagrisso US approval in unresectable lung cancer
23rd Sep 20247:05 amRNSFasenra recommended for EU approval in EGPA
23rd Sep 20247:00 amRNSFinal OS results reported for TROPION-Breast01
20th Sep 20246:00 pmRNSFluMist approved for self-administration in US
18th Sep 20247:00 amRNSFasenra EGPA US FDA approval
13th Sep 20243:15 pmRNSDirector/PDMR Shareholding
2nd Sep 20243:00 pmRNSTotal Voting Rights
16th Aug 20247:00 amRNSImfinzi approved in US for resectable lung cancer
1st Aug 20243:00 pmRNSTotal Voting Rights
30th Jul 20247:00 amRNSAstraZeneca prices a €1.4bn bond offering
29th Jul 20248:41 amRNSStabilisation Notice - ASTRAZENECA
29th Jul 20247:00 amRNSCalquence fixed-duration combo improved 1L CLL PFS
26th Jul 20247:00 amRNSODAC reviewed Imfinzi in resectable lung cancer
25th Jul 20247:00 amRNSHalf-year Report
15th Jul 20247:00 amRNSAcquisition of Amolyt Pharma completed
1st Jul 20243:00 pmRNSTotal Voting Rights
1st Jul 20247:00 amRNSLynparza & Imfinzi positive CHMP in endometrial
25th Jun 20247:05 amRNSUpdate on Imfinzi ADJUVANT BR.31 trial
25th Jun 20247:00 amRNSImfinzi improved EFS and OS in bladder cancer
18th Jun 20247:00 amRNSUpdate on CAPItello-290 Phase III trial
17th Jun 20247:00 amRNSImfinzi approved in the US for endometrial cancer
12th Jun 20243:00 pmRNSDirector/PDMR Shareholding
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
CTY
City Of London Investment
LSE
0.18%
PVG
PVG.L
LSE
0.00%
PBLT
PBLT.L
LSE
0.00%
ISP.MI
Intesa Sanpaolo
MI
-0.062%
LWI
Lowland Inv.
LSE
-0.58%
Trending
ALRT
Defence Holdings
LSE
19.05%
ITM
Itm Power
LSE
-10.85%
MKA
Mkango Resources
LSE
-3.53%
PLE
Plethora Solutions Holdings Plc
LSE
0.00%
GDR
Genedrive
LSE
6.00%